STAAR Surgical Company (STAA)
After hours:
- Investor's Business Daily
Staar Surgical Stock Earns RS Rating Upgrade
Staar Surgical shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 87.
- Zacks
Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock?
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- Business Wire
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
LAKE FOREST, Calif., June 05, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida.
